Breaking News

AVEO, Boehringer in Ficlatuzumab Manufacturing Pact

Boehringer will produce drug at Fremont site

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AVEO Pharmaceuticals and Boehringer Ingelheim have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO’s HGF inhibitory antibody currently in Phase II development in non-small cell lung cancer (NSCLC). Boehringer will produce ficlatuzumab for clinical trials at its biopharmaceutical site in Fremont, CA. AVEO retains all rights to develop and commercialize ficlatuzumab. Financial terms were not disclosed. “We believe Boehringer Ingelheim...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters